Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-04-24 Report Publication Anno…
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its main subject is the "Mise à disposition du Document d'enregistrement universel 2022" (Making available of the 2022 Universal Registration Document). It explicitly states that the Universal Registration Document (which contains the annual financial report, governance report, etc.) has been filed with the AMF and is available to the public on the company's website and the AMF website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a major report has been published or made available, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). The document is short (6113 chars) and serves primarily to announce the availability of the full 2022 Universal Registration Document.
2023-04-24 French
CARMAT - DEU 2022
Annual Report Classification · 1% confidence The document is a 'Document d'Enregistrement Universel' (Universal Registration Document) for the company CARMAT for the year 2022. This document serves as the comprehensive annual report, including the 'Rapport Financier Annuel' (Annual Financial Report), governance information, and risk factors. It is a long-form, official regulatory filing that contains audited financial statements and management analysis, fitting the definition of an Annual Report (10-K equivalent in the provided schema). FY 2022
2023-04-21 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its main subject is the announcement regarding the upcoming Annual General Meeting ("Assemblée générale mixte du 11 mai 2023") and the availability of preparatory documents, voting procedures, and participation modalities. This is an announcement concerning the AGM, not the AGM presentation itself (AGM-R) or the proxy materials (PSI). Since it is an announcement related to a shareholder meeting, and it is a formal communication, it fits best under the category related to shareholder meetings or general regulatory announcements. Given the specific focus on the AGM logistics and document availability, it is closely related to AGM information, but since it is a press release announcing the meeting and document availability, it functions as a general regulatory announcement or a precursor to the AGM/Proxy materials. However, the content is entirely focused on the logistics and documentation for the AGM. If a specific AGM-R (presentation) or PSI (proxy) is not present, this announcement serves as the official notice. Since the document explicitly discusses the AGM and the availability of related documents, and it is a formal press release, it is most accurately classified as an announcement related to the AGM process. Given the options, AGM-R is for the presentation materials. This is an announcement *about* the AGM. It is not a DEF 14A (Remuneration) or PSI (Proxy Solicitation). It is a formal notice about the meeting. In the absence of a specific 'AGM Announcement' code, and considering the content is about the AGM, I will check if it fits better as a general regulatory filing (RNS) or if it implies the AGM materials are coming. Since it announces the meeting date and document availability, it is a key step in the AGM process. Given the options, and the strong focus on the AGM, I will classify it as AGM-R, interpreting it as the primary communication related to the AGM, although RPA or RNS might also be plausible if the document were shorter and only pointed to other documents. Given its length and detail about the meeting, AGM-R is the most contextually relevant choice among the specific meeting codes, even if it's a notice rather than the presentation itself. Re-evaluating based on the 'MENU VS MEAL' rule: This document *announces* the AGM and states documents are available, making it an announcement rather than the full AGM presentation (AGM-R) or the proxy statement (PSI). Therefore, it is best classified as a general regulatory announcement (RNS) because it is a press release detailing administrative/procedural information about an upcoming event, rather than the core content of the AGM presentation or the proxy materials themselves. It is a formal communication to shareholders about the meeting logistics.
2023-04-20 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is a formal declaration dated April 19, 2023, made under Article 223-16 of the General Regulation of the Autorité des marchés financiers (AMF). It explicitly details the 'nombre total de droits de vote et d'actions composant le capital social' (total number of voting rights and shares comprising the share capital) as of March 31, 2023. This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing, often related to capital structure updates or pre-AGM requirements, but it most closely aligns with a general regulatory announcement or a specific capital/share structure notification. Given the options, it is a specific regulatory disclosure about the capital structure. While it relates to shares (SHA) or voting rights (DVA), the context is a mandatory periodic disclosure of the total share count and voting rights, which is a common component of regulatory reporting. Since it is not a dividend announcement (DIV), a director's dealing (DIRS), or a proxy statement (PSI), and it is a formal regulatory declaration, it fits best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA) if the focus is strictly on the share count change. However, the primary purpose is reporting the total voting rights and shares as mandated by the AMF regulation, making RNS the most appropriate general regulatory fallback if a more specific code isn't perfect. Upon review, this specific type of filing (total voting rights disclosure) is often categorized separately or under general regulatory announcements. Given the options, and since it is a formal declaration to the regulator about the capital structure, RNS (Regulatory Filings) is the safest general classification, although it touches upon capital structure elements. Let's re-evaluate against DVA (Declaration of Voting Results & Voting Rights Announcements). DVA is for *results* from shareholder votes. This document is about the *total number* of voting rights attached to the capital, not the results of a vote. Therefore, RNS is the best fit as a mandatory regulatory disclosure that doesn't fit the other specific categories perfectly.
2023-04-19 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the publication of clinical experience with the Aeson® TAH in the "Annals of Thoracic Surgery Short Reports." It contains key highlights, CEO commentary, company background, and contact information typical of a corporate news release regarding a significant event (publication of clinical data). This structure strongly indicates an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing a specific, non-financial milestone (a publication), and it is not a full financial report (like 10-K or IR), it fits best as a general announcement. However, given the context of financial reporting databases, press releases announcing significant operational/clinical milestones are often categorized as Earnings Releases (ER) if they are periodic updates, or Regulatory Filings (RNS) if they are ad-hoc. Since this is a specific, non-periodic announcement about a publication, and it is not a formal regulatory filing like a 10-K or a dividend notice, the most appropriate general category for a significant, non-financial corporate announcement that doesn't fit other specific codes is RNS (Regulatory Filings/General Announcement). If the database prioritizes operational news releases, ER might be considered, but RNS is the safer fallback for non-standard announcements. Given the content is a press release about a publication, RNS is the most fitting general category.
2023-03-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the publication of clinical results in a medical journal. It provides key highlights, quotes from management, and contact information for press/investors. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing ownership changes or dividends. Since it is an announcement of news/results, it fits best under the general category for announcements that aren't strictly financial results (ER) or specific corporate actions. Given the content is a major operational/clinical update, and it is a press release format, the most appropriate general category among the options that covers non-standard announcements is 'Regulatory Filings' (RNS) as a fallback, although 'Earnings Release' (ER) is sometimes used loosely for major announcements. However, since this is a clinical/scientific publication announcement, and not a financial earnings announcement, RNS (Regulatory Filings/General Announcement) is the most suitable catch-all for significant, non-standard corporate news releases.
2023-03-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.